The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Barriers to accessing reni-cel for the treatment of SCD
Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses barriers to gene therapy with renizgamglogene autogedtemcel (reni-cel) for treating sickle cell disease (SCD), particularly its limited access in developing countries where the disease is most prevalent. He also emphasizes the importance of access to supportive care, noting that patients often fear infertility as a significant concern related to this treatment. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: SOBI, Sanofi
Honoraria: Vertex
Research Funding: EDITAS
